Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint

21.07.2023 - Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of SLE did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which ...

Related Keywords

United States , Lang Schwarz , Linkedin , Twitter , Exchange Commission , Facebook , Instagram , Daxdilimab Phase , Systemic Lupus , Systemic Lupus Erythematosus Responder Index , Looking Statements , United States Securities , Horizon Therapeutics Stock ,